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Acquired Immuno Deficiency Syndrome (AIDS) is an infection caused by the Human 
Immunodeficiency Virus (HIV). The antiretrovirals (ARVs) combination is the basis for the 
management of therapy in HIV/AIDS patients, but it often raises problems like adverse drug reactions 
(ADRs). This study was conducted to determine the risk factors for the occurrence of ADRs in the use 
of first-line ARVs. It employed a cross-sectional design with retrospective data collection in patients 
visiting the Voluntary Cell Counting (VCT) room of RSUD Dr. Moewardi in November-December 
2018. The data collected were sociodemographic, behavioral, and clinical characteristics, laboratory 
test results, and ARV profiles. Findings show that the risk factors for ADRs in the use of first-line 
ARVs are CD4 of <200 and 0-24 months of taking ARVs. 
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Acquired immune deficiency syndrome (AIDS) is a disease caused by infections by the human 
immunodeficiency virus (HIV). HIV does not directly cause death but decreases body immunity 
instead, resulting in susceptibility to opportunistic infections (Ibrahim and 2017). Antiretrovirals 
(ARVs) combination is the basic principle of antiretroviral therapy for HIV/AIDS patients because it 
can reduce resistance, effectively suppress HIV replication, opportunistic infections, and other 
complications, and improve the quality and life expectancy of HIV/AIDS patients. Early therapy can 
protect the immune system from HIV-induced damages (Masenyetse et al., 2015). 
Problems arising from the use of ARVs include adverse drug reactions or ADRs (Li et al., 
2017). This research is expected to help monitor and report the occurrence and risk factors of ADRs in 
patients receiving first-line antiretroviral therapy in Dr. Moewardi hospital. 
 
METHOD 
This research has been granted with an ethical clearance No. 758/XI/HREC/2018. It used a 
cross-sectional design with retrospective data collection in patients who visited the Voluntary Cell 
Counting (VCT) room of RSUD Dr. Moewardi, Surakarta, Indonesia, in November-December 2018. 
These data were sociodemographic, behavioral, and clinical characteristics, laboratory test results, and 
ARV profiles. 
The research population was HIV-infected patients who received first-line ARV regimen 
therapy in the VCT room of RSUD Dr. Moewardi and met the inclusion and exclusion criteria. The 
inclusion criterion was the willingness to be involved in the study (participation was confirmed by 
filling out and signing an informed consent form). Meanwhile, the exclusion criteria were unstable 
mental conditions obtained from medical records (these conditions were believed to make them unable 
to provide information related to the perceived ADR) and age of <18 years (to facilitate the interview 
process). As a result, 204 patients were selected as the research population. In this study, the sample 
size was determined using the proportion-based formula by (Lameshow et al., 1997). 
  
n   n  41 people (minimum sample). 
where: 
n : number of samples 
N : number of population 
Z²1-α / 2 : standard normal distribution values (table Z) at 95% confidence level (1960) 
p : estimated population proportion of 86.7% (Mendes et al., 2018) 
q : 1-p (1-0.867 = 0.133) 
d : tolerable errors (absolute) (0.1) 
 
This calculation yielded a minimum of 41 samples.  
The research variables included independent and dependent variables. An independent variable 
is a variable that influences or causes a change in the appearance of a dependent variable. A dependent 
variable is a variable that is affected or appears because of the independent variable. In this study, the 
independent variables were sociodemographic, behavioral, and clinical characteristics, laboratory test 
results, and antiretrovirals (ARVs) profiles, while the dependent variable was the occurrence of ADRs. 
The first interview was intended to find out ADRs using the Naranjo algorithm-based questionnaire of 
the ADR probability scale (Badan Pengawas Obat dan Makanan Republik Indonesia, 2012) and 
conducted when participants visited the Voluntary Counseling and Testing (VCT) room. During 
which, information on patient characteristics, clinical characteristics, laboratory test results, and ARV 
profiles was gathered using patients data collection sheets. The second to fourth interviews were 
conducted by phone once a week using the same questionnaire to find out any occurrences of ADRs 
Pharmaciana ISSN: 2088 4559; e-ISSN: 2477 0256  
 






(Badan Pengawas Obat dan Makanan Republik Indonesia, 2012), with the help of the Medical Doctor 
in Charge (MDIC) of the VCT room. 
 
Data Analysis 
Answers recorded in the questionnaires were then analyzed in the Statistical Package for Social 
Sciences (SPSS) v.20 program. A univariate analysis was performed to define the distributions of 
sociodemographic, behavioral, and clinical characteristics, laboratory test results, and ARV profiles. 
Meanwhile, a bivariate analysis was conducted to explore the correlation between ADRs and their risk 
factors using the Chi-square or Fisher's exact tests (if the Chi-square test did not meet the expected 
count value), with p-values of ≤0.05 indicating a significant correlation. The analyses were carried out 
at 5% confidence level (α = 0.05), with a 95% confidence interval. 
 
RESULT AND DISCUSSION 
Adverse Drug Reactions are expressions of intrinsic intolerance to the accumulation of 
substances that are considered toxic. In this study, there were 204 patients, 176 of which (86%) 
experienced ADRs, while the remaining 28 patients (14%) did not. These results are similar to Kumari 
et al. (2017), i.e., patients who experienced ADRs have a larger proportion (228 people, 81.4%) than 
those who did not (52 people, 18.6%). The types of ADRs detected in this study were anemia, 
neutropenia, myopathy, dyspepsia, nausea, vomiting, kidney toxicity, drowsiness, insomnia, weight 
loss, dizziness, hepatotoxicity, rash, and pruritus. 
 
ARV profiles 
Zidovudine (AZT) is the first choice of drug in the combination of first-line ARV regimens 
because AZT is known to be well-tolerated and available in many combination preparations (Fixed-
Dose Combination). The most used combination is Zidovudine + Lamivudine + Nevirapine/Efavirenz 
because it is the first choice set by the Indonesian government for patients who do not have 
abnormalities in their liver and blood function. Lamivudine is the first choice of the NRTI class 
because it is safe, effective for hepatitis B, and widely available, including in a fixed-dose 
combination. The second choice from the NRTI class is Zidovudine because its side effects are 
generally easily tolerated and it rarely causes metabolic complications. Meanwhile, tenofovir in ARV 
regimens functions as a substitute for the previous ARV regimens. Antiretroviral replacement in 
patients can be prompted by toxicity reasons, where patients are unable to overcome the ADR from 
previous drugs, or by a failure of previous therapy, as evident from CD4 values (disease progression) 
(Hidayati et al., 2016). The result of ARV profiles can be seen in Table 1. 
 
Table 1. Characteristics of antiretrovirals (ARVs) received by HIV patients in RSUD  
Dr. Moewardi in November-December 2018 
Characteristics of ARVs 
Number of patients 
N = 204 
 
Number of patients 
experiencing ADRs 
N = 176 
 
Percentage of ADR 
occurrences% 
 
Types of ARV used    
AZT/3TC/NVP 93 77 82.7 
AZT/3TC/EFV 58 51 87.9 
TDF/3TC/NVP 9 9 100.0 
TDF/3TC/EFV 44 39 88.6 
Durations of ARV use    
1-6 months 17 17 100.0 
7-12 months 38 37 97.3 
13-24 months 48 41 85.4 
25-36 Months 36 31 86.1 
≥ 37 months 65 50 76.9 
Mean ± SD* 34 ± 26 32 ± 26.9  
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These results are consistent with Eluwa et al. (2012), which suggested that the highest 
likelihood of ADRs is in the first six months of ARV use. (Namme Luma et al., 2012) proved that 1 of 
5 patients (19.5%) taking antiretroviral drugs experienced ADRs after less than one month of their 
antiretroviral therapy. Also, Tadesse et al. (2014) explained that ADRs occurred in 66% of patients 
taking ARVs for ≤ 1 month and in 51.7% of patients taking ARVs for > 1 month. 
Sociodemographic characteristics 
In this study, male HIV patients were higher in number than their female counterparts. This 
finding is similar to the data of the Directorate General of Disease Prevention and Control (Direktorat 
Jenderal Pencegahan dan Pengendalian Penyakit, 2017), i.e., the ratio of male to female HIV patients 
is 2:1. HIV/AIDS cases in men are higher because it is believed to be associated with sexual behavior 
as a precursor of transmission to and from commercial sex workers (CSWs) and men who have sex 
with men (MSM). Men reportedly exhibit more of this behavior compared to women (Butarbutar et 
al.,2014; Yuliandra et al., 2017). Table 2 show us the sociodemographic characteristics of HIV 
patients at RSUD Dr.Moewardi in November-December 2018. 
 




Number of patients 
N = 204 
 
Number of patients 
experiencing ADRs 
N = 176 
 
Percentage of ADR 
occurrences% 
 
    
Sex     
Male  127 111 87.4 
Female 77 65 84.4 
Age    
< 60 years 191 165 86.3 
≥ 60 years 13 11 84.6 
Mean ± SD 40.7 ± 10.8 40 ± 10.5  
Marital Status    
Married 160 140 87.5 
Single 44 36 81.8 
Education     
Primary school 33 27 81.8 
Junior high school 40 35 87.5 
Senior high school 91 81 89.0 
Bachelor 40 33 82.5 
SD: Standard Deviation 
 
Based on age, the sampled patients were categorized into two categories, namely, adult (17-59 
years old) and elderly (≥60 years old). Sociodemographically, a larger share of the patients was adult, 
ranging from the youngest, 19, to the oldest, 78. Butarbutar et al. (2014) explain that the number of 
HIV/AIDS cases is high in the adult group, i.e., sexually active and productive age range. 
A total of 160 sampled patients were married, which were larger than the unmarried ones. This 
result is similar to Anwar et al. (2018), which explained that HIV cases are found in a more substantial 
number in married patients (75.8%). In this context, being married increases the risk of transmission of 
HIV infection through sexual contact and from mothers to their children during pregnancy, birth, and 
breastfeeding. 
Patients with an upper secondary educational level, i.e., senior high school (SMA), contributed 
the highest to cases of HIV/AIDS, which amounted to 91 patients. Meanwhile, the least cases were 
found in those with a lower secondary educational level (elementary school; SD), which was up to 33 
patients. HIV/AIDS affected all levels of education. Someone with high educational attainments that 
assumably have good knowledge of HIV/AIDS does not necessarily stay away from the spread of HIV 
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infection (Butarbutar et al., 2014). Similarly, Kambu et al. (2016) signify the absence of a significant 
relationship between education level and transmission prevention measures. 
 
Behavioral Characteristics 
Among the sampled patients, 11 were illegal users of narcotics and psychotropic drugs. 
Compared to those who were not, the prevalence of ADRs in this group was higher (90.9%). This 
result is inconsistent with  Pádua (2006), where ADRs were identified more in patients who used drugs 
illegally (92 people, 34.7%) than those who did not (28 people, 28.9%). Drug abuse can cause 
unfavorable interactions with ARVs, leading to changes in ARV absorption and metabolism (Mendes 
et al., 2018). Behavioral characteristics can be seen in Table 3. 
Table 3. The characteristics of the behavior of HIV patients at RSUD Dr. Moewardi in 
November-December 2018 
Behavioral Characteristics 
Number of patients 
N = 204 
 
Number of patients 
experiencing ADRs 
N = 176 
 
Percentage of ADR 
occurrences% 
 
Drug users    
Yes 11 10 90.9 
No 193 166 86.0 
Alcohol users    
Yes 23 19 82.6 
No 181 157 86.7 
 
ADRs appeared in patients who consumed alcohol (19 people) and those who did not (157 
people). ADRs were found in a large proportion of the latter (86.7%), which was higher in percentage 
than the former. In antiretroviral therapy, both alcohol and drug abuse can lead to pharmacokinetic 
interactions because these substances are all metabolized in the liver. Drug interactions are a precursor 
of ADRs; therefore, extra cautions are needed when prescribing ARVs for patients with liver 
dysfunction. In this context, controlling potential pharmacokinetic interactions can include the medical 
team providing counseling that recommends patients to reduce or stop using alcohol and drugs 
illegally as an attempt to reduce the probability of ADRs (Pádua, 2006). 
 
Clinical characteristics 
Among the 204 sampled patients, 52 were co-infected and 152 were not co-infected. Most co-
infection was tuberculosis (TB, in 45 people), while hepatitis co-infection was the least (7 people). 
These results are similar to Butarbutar et al. (2014), which stated that the most frequent co-infection is 
tuberculosis infection (48.8%). TB is associated with damages to the cellular immune system; hence, 
TB infection can attack HIV patients very easily (Butarbutar et al., 2014), leading to a high rate of TB 
co-infection. The results about clinical characteristic of HIV patients can be seen in Table 4. 
 




Number of patients 
N = 204 
 
Number of patients 
experiencing ADRs 






Co-infections    
TBC 45 38 84,4 
Hepatitis 7 7 100,0 
 
ADRs were detected in 38 patients with TB co-infection and 7 patients with hepatitis co-
infection. However, the percentage shows that ADRs were more prevalent in patients with hepatitis 
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co-infection (100%) than the ones with tuberculosis. In antiretroviral therapy, hepatitis is a common 
ADR due to the use of anti-tuberculosis drugs, and liver function is reportedly improves after patients 
no longer take these drugs (Rimfampicin). Anti-tuberculosis drugs can contribute to ADRs, and these 
types of reactions account for 28.3% of the total ADR cases (Kumar et al., 2015). Drugs administered 
for co-infection therapy can increase the probability of ADRs due to cumulative toxicity or drug 
interactions. Opportunistic hepatitis or tuberculosis infections with the use of antiretroviral drugs can 
increase the risk of hepatotoxicity (Prosperi et al., 2012). 
 
Laboratory test results 
Among the sampled patients, 141 had CD4 counts of >200 cells/mm
3
, which was larger than the 
number of patients with CD4 < 200 cells/mm
3
. In this study, CD4 counts ranged from 5 to 786 
cells/mm
3
, with an average of 286.1 cells/mm
3
. Table 5 show us Characteristics of laboratory test 
results of HIV patients at RSUD Dr. Moewardi in November-December 2018. 
 
Table 5. Characteristics of laboratory test results of HIV patients at RSUD  
Dr. Moewardi in November-December 2018 
Laboratory test results 
Number of patients 
N = 204 
 
Number of patients 
experiencing ADRs 
N = 176 
 
Percentage of ADR 
occurrences% 
 
CD4    
≤200 63 59 93.6 
>200 141 117 82.9 
Mean ± SD* 286.1 ± 155.3 278.4 ± 156.4  
 
This result is similar to Lartey et al. (2014), where CD4 counts of more than 250 cells/mm
3
 are 
associated with a reduced number of ADR cases. Similarly, Mendes et al. (2018) confirm that patients 
with CD4 counts of <200 cells/mm
3
 have to receive additional drugs to prevent opportunistic 
infections, increasing the occurrences of ADRs. 
 
Risk factors for adverse drug reactions (ADRs) 
Risk factors are conditions that influence the development of certain diseases or health status. In 
this study, the CD4 count was found to be significantly correlated with ADRs, as evidenced by p-
value<0.05. Patients with CD4 <2 00 cells/mm
3
 had 3.026 times higher risks of experiencing ADRs 
than patients with CD4 > 200 cells/mm
3
. These results are similar to Modayil and Harugeri (2011), 
which also confirm the significant relationship between CD4 counts and ADRs (p= 0.025). Eluwa et 
al. (2012) and Tatiparthi and Mamo (2015) correlate low CD4 counts to the occurrences of ADRs in 
most patients with < 200 cells/mm
3
. Risk Factors for ADRs in the First-Line ARV therapy can be seen 
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Table 6. Risk factors for ADRs in the first-line ARV therapy 
Characteristics 
Adverse drug reactions P-value 
 
OR (CI 95%) 
Yes No 
Gender      
Male  111 (63.1) 16 (57.1)   
Female 65 (36.9) 12 (42.9) 0.548 1.281 (0.571-2.875) 
Age     
< 60 years 165 (93.8) 26 (92.9)   
≥ 60 years 11 (6.2) 2 (7.1) 0.694* 1.154 (0.242-5.504) 
CD4 counts 
    
≤200 59 (33.5) 4 (14.3) 
  
>200 117 (66.5) 24 (85.7) 0.041 3.026 (1.003-9.124) 
Duration of ARV use 
   
0-24 months 95 (54.0) 8 (28.6) 
  
≥ 25 months 81 (46.0) 20 (71.4) 0.013 2.932 (1.226-7.012) 
* the Fisher’s exact test 
 
CD4 is a special type of lymphocytes most affected by the Human Immunodeficiency Virus 
(HIV). HIV is associated with a decrease in CD4 counts as it infects CD4 and causes the death of this 
cell once it enters the body. Lowered CD4 counts indicate the level of damage to the immune system, 
increasing the vulnerability of HIV-infected bodies to various types of diseases. CD4 examination is 
carried out together with the administration of the ARV regimen and once every six months as a 
reference for starting, controlling, and changing the regimen given. Data on CD4 counts before and 
during the ARV therapy can provide information on whether the therapy succeeds or fails (Anwar et 
al., 2018; Butarbutar et al., 2014).  
HIV-infected patients with CD4 counts of averagely 50350 cells/mm
3
 need to begin 
antiretroviral therapy immediately. If the CD4 count is ≤200 cells/mm3, Cotrimoxazole 1 x 960 mg 
was prescribed for two weeks to prevent opportunistic infections, followed by ARVs. Immunity can be 
evaluated by observing the average counts of CD4. After the administration of ARVs, the CD4 count 
of 70-100 cells/mm
3
/year can change to 50-100 cells/mm
3
/year. Patients who have never reached CD4 
counts of 100 cells/mm
3
 or experienced a progressive decreased in CD4 counts after reaching a high 
count without any other medical conditions are suspected for immunological failure. Immunological 
failure in the ARV therapy occurs in three patterns: (1) CD4<100 cells/mm
3
 after one year of ARV 
therapy, (2) after one year of therapy, the CD4 count recovers or becomes lower than at the beginning 
of the therapy, and (3) CD4 count decreases to 50% of the highest CD4 count ever reached during the 
therapy. Changes are made to current antiretroviral therapy if the CD4 count remains at <200 
cells/mm
3
 during one year of the therapy (Kementerian Kesehatan Republik Indonesia - Direktorat 
Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan, 2011).  
This study shows that the length of ARV therapy is significantly related to the occurrences of 
ADRs, as apparent from p-value<0.05. Prolonged use of ARVs, 0-24 months, creates 2.932 times 
higher risk of experiencing ADRs compared to patients having taken ARVs for 25 months. These 
results are similar to Eluwa et al. (2012), which found that ADRs are most likely to occur during the 
first six months of ARV therapy. Early use of antiretroviral drugs before CD4 counts decline and 
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Adverse Drug Reactions (ADRs) have been found in 176 sampled patients (86%) but not in the 
other 28 patients (14%). The significant risk factors for ADRs in the use of first-line ARVs are CD4 
counts <200 cells/mm
3
 and 0-24 months of taking antiretroviral drugs. 
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